Represents the percent of calculation of compensation rate by using gross sales price per share sold.

No definition available.

Name:	mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent
Namespace Prefix:	mrkr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems
Namespace Prefix:	mrkr_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Funds received from grant.

+ References

No definition available.

+ Details

Name:	mrkr_FundsReceivedFromCpritGrant
Namespace Prefix:	mrkr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Funds received from grant

+ References

No definition available.

+ Details

Name:	mrkr_FundsReceivedFromGrant
Namespace Prefix:	mrkr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	mrkr_GrantAssistanceTerm
Namespace Prefix:	mrkr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.

+ References

No definition available.

+ Details

Name:	mrkr_GrantReceived
Namespace Prefix:	mrkr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481142/505-10-45-2

+ Details

Name:	us-gaap_CommonStockSharesSubscriptions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrkr_FdaGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrkr_AdditionalCpritGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LIQUIDITY AND FINANCIAL CONDITION (Details) - USD ($)			1 Months Ended							3 Months Ended
LIQUIDITY AND FINANCIAL CONDITION (Details) - USD ($)	Dec. 23, 2024	Dec. 19, 2024	Dec. 31, 2024	Nov. 30, 2024	Aug. 31, 2024	Jun. 30, 2024	May 31, 2023	Sep. 30, 2022	Aug. 31, 2021	Mar. 31, 2026	Dec. 31, 2025	Mar. 31, 2025
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Cash, cash equivalents and restricted cash			$ 19,192,440							$ 15,638,655	$ 17,042,847	$ 13,693,208
Product development research award									$ 13,100,000
Funds received from CPRIT grant										11,800,000
Market Offering
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Aggregate offering price				$ 11,431,713
Commission rate				3.00%
Private Placement
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Net proceeds from the sale of securities	$ 14,900,000
Private Placement \| Pre Funded Warrant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Issuance of shares of common stock		3,247,445
Purchase price (in dollars per share)		$ 3.199
Private Placement \| Private Placement Warrant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Issuance of shares of common stock		5,031,250
Private Placement \| Common Stock
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Number of shares issued (in shares)		1,783,805
Purchase price (in dollars per share)		$ 3.2
FDA Grant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Grant income received								$ 2,000,000
Funds received from grant										1,200,000
SBIR AML Grant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Grant income received							$ 2,000,000
Funds received from grant										1,800,000
National Institutes of Health National - Cancer Institute Grant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Grant income received						$ 2,000,000
Funds received from grant										600,000
Grant assistance term						2 years
SBIR lymphoma grant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Grant income received					$ 2,000,000
Funds received from grant										1,300,000
SBIR pancreatic cancer grant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Grant income received					$ 2,000,000
Funds received from grant										500,000
Additional CPRIT grant
FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS
Grant income received			$ 9,500,000
Funds received from grant										$ 1,500,000